May 12, 2023 04:01PM
Mar 10, 2023 07:30AM
Feb 13, 2023 08:05AM
Feb 13, 2023 08:05AM
Dec 19, 2022 07:30AM
Dec 15, 2022 07:30AM
Nov 17, 2022 07:30AM Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
Nov 8, 2022 04:05PM
Oct 12, 2022 07:30AM
Aug 9, 2022 04:05PM
May 4, 2022 04:30PM
Mar 15, 2022 07:30AM
Dec 9, 2021 07:31AM
Dec 9, 2021 07:30AM Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
Nov 15, 2021 07:30AM
Nov 9, 2021 07:30AM
Oct 27, 2021 07:30AM
Oct 21, 2021 07:30AM
Sep 22, 2021 07:31AM
Sep 22, 2021 07:30AM
Aug 12, 2021 07:30AM Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
May 20, 2021 08:30AM
May 13, 2021 07:30AM
Mar 29, 2021 04:01PM
Mar 23, 2021 09:28AM
Mar 23, 2021 07:02AM
Mar 23, 2021 07:00AM
Feb 22, 2021 04:01PM Frequency Therapeutics (FREQ) Reports Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322
Feb 22, 2021 04:00PM
Feb 10, 2021 04:10PM
Dec 18, 2020 08:00AM
Nov 16, 2020 07:30AM
Oct 29, 2020 07:00AM
Sep 22, 2020 07:33AM
Sep 22, 2020 07:30AM Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
Sep 13, 2020 03:00PM
Aug 12, 2020 07:30AM
Jul 17, 2020 04:06PM
Jul 17, 2020 04:05PM
Jul 14, 2020 09:24AM
Jul 13, 2020 05:35PM
Jul 13, 2020 04:07PM Oppenheimer Starts Frequency Therapeutics (FREQ) at Outperform
May 14, 2020 08:18AM
May 14, 2020 07:30AM
May 14, 2020 07:15AM
Mar 26, 2020 07:00AM
Nov 18, 2019 07:30AM
Oct 10, 2019 08:35AM
Oct 10, 2019 08:30AM Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

322,897 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All